Cancer and Blood Specialty Clinic Adopts Deep Lens’ Clinical Trial Matching Solution VIPER™ to Broaden Clinical Research Program
Retrieved on:
Wednesday, July 7, 2021
Data management, Other Health, Technology, Pharmaceutical, Practice Management, Oncology, Managed care, Hospitals, Clinical trials, Science, Biotechnology, Software, Other Science, Health, Research, Medicine, Cancer, Screening, Health, Clinical medicine, Oncology, the Cancer and Blood Specialty Clinic, Deep Lens, THE CANCER AND BLOOD SPECIALTY CLINIC, DEEP LENS
The Cancer and Blood Specialty Clinic (CBSC) and Deep Lens announced today that they have entered into a strategic partnership to integrate artificial intelligence (AI)-based clinical trial matching solution, VIPER, into the Southern California-based practice.
Key Points:
- The Cancer and Blood Specialty Clinic (CBSC) and Deep Lens announced today that they have entered into a strategic partnership to integrate artificial intelligence (AI)-based clinical trial matching solution, VIPER, into the Southern California-based practice.
- The majority of cancer patients are diagnosed and treated at community oncology practices, like the Cancer and Blood Specialty Clinic.
- Like the Cancer and Blood Specialty Clinic, any practice that utilizes CureMD can easily integrate VIPER and all other Deep Lens screening services free of charge.
- Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.